Radiotherapy of T4 bladder carcinoma.
A 16% 5-year crude survival was observed in 159 irradiated patients with T4NXMO bladder carcinoma. The presence of a T4a tumour and a good performance status were important prognostic parameters. The combination of radiotherapy and weekly injections of 5-FUra (12 mg/kg) resulted in a significant 2-year survival increase. New regimens of combined radiotherapy/chemotherapy should be developed for patients with T4NXMO bladder carcinoma. The palliation effect of radiotherapy should further be evaluated, preferably in prospective studies comparing radiotherapy with other types of palliation treatment.